Literature DB >> 26542950

Organization of infection control in European hospitals.

S Hansen1, W Zingg2, R Ahmad3, Y Kyratsis4, M Behnke5, F Schwab5, D Pittet2, P Gastmeier5.   

Abstract

BACKGROUND: The Prevention of Hospital Infections by Intervention and Training (PROHIBIT) survey was initiated to investigate the status of healthcare-associated infection (HCAI) prevention across Europe. AIM: This paper presents the methodology of the quantitative PROHIBIT survey and outlines the findings on infection control (IC) structure and organization including management's support at the hospital level.
METHODS: Hospitals in 34 countries were invited to participate between September 2011 and March 2012. Respondents included IC personnel and hospital management.
FINDINGS: Data from 309 hospitals in 24 countries were analysed. Hospitals had a median (interquartile range) of four IC nurses (2-6) and one IC doctor (0-2) per 1000 beds. Almost all hospitals (96%) had defined IC objectives, which mainly addressed hand hygiene (87%), healthcare-associated infection reduction (84%), and antibiotic stewardship (66%). Senior management provided leadership walk rounds in about half of hospitals, most often in Eastern and Northern Europe, 65% and 64%, respectively. In the majority of hospitals (71%), sanctions were not employed for repeated violations of IC practices. Use of sanctions varied significantly by region (P < 0.001), but not by countries' healthcare expenditure.
CONCLUSION: There is great variance in IC staffing and policies across Europe. Some areas of practice, such as hand hygiene, seem to receive considerably more attention than others that are equally important, such as antibiotic stewardship. Programmes in IC suffer from deficiencies in human resources and local policies, ubiquitous factors that negatively impact on IC effectiveness. Strengthening of IC policies in European hospitals should be a public health priority.
Copyright © 2015. Published by Elsevier Ltd.

Entities:  

Keywords:  Europe; Healthcare-associated infection prevention; Hospital

Mesh:

Year:  2015        PMID: 26542950     DOI: 10.1016/j.jhin.2015.07.011

Source DB:  PubMed          Journal:  J Hosp Infect        ISSN: 0195-6701            Impact factor:   3.926


  16 in total

Review 1.  Epidemiology of antimicrobial resistance in bloodstream infections.

Authors:  Murat Akova
Journal:  Virulence       Date:  2016-04-02       Impact factor: 5.882

2.  Prevention of hospital infections by intervention and training (PROHIBIT): results of a pan-European cluster-randomized multicentre study to reduce central venous catheter-related bloodstream infections.

Authors:  Tjallie van der Kooi; Hugo Sax; Didier Pittet; Jaap van Dissel; Birgit van Benthem; Bernhard Walder; Vanessa Cartier; Lauren Clack; Sabine de Greeff; Martin Wolkewitz; Stefanie Hieke; Hendriek Boshuizen; Jan van de Kassteele; Annemie Van den Abeele; Teck Wee Boo; Magda Diab-Elschahawi; Uga Dumpis; Camelia Ghita; Susan FitzGerald; Tatjana Lejko; Kris Leleu; Mercedes Palomar Martinez; Olga Paniara; Márta Patyi; Paweł Schab; Annibale Raglio; Emese Szilágyi; Mirosław Ziętkiewicz; Albert W Wu; Hajo Grundmann; Walter Zingg
Journal:  Intensive Care Med       Date:  2017-12-16       Impact factor: 17.440

Review 3.  Comparison of governance approaches for the control of antimicrobial resistance: Analysis of three European countries.

Authors:  Gabriel Birgand; Enrique Castro-Sánchez; Sonja Hansen; Petra Gastmeier; Jean-Christophe Lucet; Ewan Ferlie; Alison Holmes; Raheelah Ahmad
Journal:  Antimicrob Resist Infect Control       Date:  2018-02-20       Impact factor: 4.887

4.  Evaluating infection prevention and control programs in Austrian acute care hospitals using the WHO Infection Prevention and Control Assessment Framework.

Authors:  Seven Johannes Sam Aghdassi; Andrea Grisold; Agnes Wechsler-Fördös; Sonja Hansen; Peter Bischoff; Michael Behnke; Petra Gastmeier
Journal:  Antimicrob Resist Infect Control       Date:  2020-06-22       Impact factor: 4.887

5.  Process and outcome indicators for infection control and prevention in European acute care hospitals in 2011 to 2012 - Results of the PROHIBIT study.

Authors:  Sonja Hansen; Frank Schwab; Walter Zingg; Petra Gastmeier
Journal:  Euro Surveill       Date:  2018-05

6.  A national survey on the implementation of key infection prevention and control structures in German hospitals: results from 736 hospitals conducting the WHO Infection Prevention and Control Assessment Framework (IPCAF).

Authors:  Seven Johannes Sam Aghdassi; Sonja Hansen; Peter Bischoff; Michael Behnke; Petra Gastmeier
Journal:  Antimicrob Resist Infect Control       Date:  2019-05-08       Impact factor: 4.887

7.  What are the main drivers for public policies to prevent healthcare-associated infections?

Authors:  M C Padoveze; C Nogueira-Jr; J Tanner; S Timmons
Journal:  J Hosp Infect       Date:  2018-12-13       Impact factor: 3.926

8.  Multimodal strategy in surgical site infections control and prevention in orthopaedic patients - a 10-year retrospective observational study at a Polish hospital.

Authors:  Małgorzata Kołpa; Roża Słowik; Marta Wałaszek; Zdzisław Wolak; Anna Różańska; Jadwiga Wójkowska-Mach
Journal:  Antimicrob Resist Infect Control       Date:  2020-01-23       Impact factor: 4.887

9.  Mortality review as a tool to assess the contribution of healthcare-associated infections to death: results of a multicentre validity and reproducibility study, 11 European Union countries, 2017 to 2018.

Authors:  Tjallie van der Kooi; Alain Lepape; Pascal Astagneau; Carl Suetens; Mioara Alina Nicolaie; Sabine de Greeff; Ilma Lozoraitiene; Jacek Czepiel; Márta Patyi; Diamantis Plachouras
Journal:  Euro Surveill       Date:  2021-06

10.  European intensive care physicians' experience of infections due to antibiotic-resistant bacteria.

Authors:  Alain Lepape; Astrid Jean; Jan De Waele; Arnaud Friggeri; Anne Savey; Philippe Vanhems; Marie Paule Gustin; Dominique L Monnet; José Garnacho-Montero; Anke Kohlenberg
Journal:  Antimicrob Resist Infect Control       Date:  2020-01-02       Impact factor: 4.887

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.